0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
In the Balance |

BiDil for Heart Failure in Black Patients: Implications of the U.S. Food and Drug Administration Approval

Kirsten Bibbins-Domingo, PhD, MD; and Alicia Fernandez, MD
[+] Article and Author Information

From the University of California, San Francisco, San Francisco, California.


Acknowledgments: The authors thank the organizers and participants of the special symposium on the implications of BiDil at the 2005 Society of General Internal Medicine Annual Meeting, New Orleans, Louisiana, 11–14 May 2005, including Drs. Giselle Corbie-Smith, Carol Horowitz, Valerie Stone, Christopher Phillips, and Jack Geiger.

Grant Support: Dr. Bibbins-Domingo is supported by grants from the Robert Wood Johnson Foundation (Amos Medical Faculty Development award) and the National Heart, Lung, and Blood Institute (contract no. N01-HC-95095), and Dr. Fernandez is supported by a K23 award from the National Center for Research Resources of the National Institutes of Health (K23 RR01832401).

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Kirsten Bibbins-Domingo, PhD, MD, Division of General Internal Medicine, San Francisco General Hospital, University of California, San Francisco, Box 1364, San Francisco, CA 94143-1364; e-mail, bibbinsk@medicine.ucsf.edu.

Current Author Addresses: Drs. Bibbins-Domingo and Fernandez: Division of General Internal Medicine, San Francisco General Hospital, University of California, San Francisco, Box 1364, San Francisco, CA 94143-1364.


Ann Intern Med. 2007;146(1):52-56. doi:10.7326/0003-4819-146-1-200701020-00009
Text Size: A A A

In 2005, the combination of hydralazine hydrochloride and isosorbide dinitrate was approved by the U.S. Food and Drug Administration (FDA) for treating heart failure in black patients. In departing from its long history of approving drugs for general clinical indications without regard to demographic classification, the FDA cited the need to address racial disparities in health as an important contributor to their decision. The authors argue that this decision, although perhaps well-intentioned, was based on flawed scientific interpretation of trial results that claimed differential drug response by race and ignored the considerable literature on the cause of racial disparities in health and health care. Because of its potential impact on future drug approvals, the FDA's decision is a setback in the scientific and policy discourse on medical therapeutics and race and specifically hinders the efforts aimed at eliminating health and health care disparities.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Correction
Posted on January 16, 2007
Kirsten Bibbins-Domingo
University of California, San Francisco
Conflict of Interest: None Declared

This article incorrectly states that "increased levels of nitric oxide in black people that are associated with adverse heart failure outcomes and may be reduced by hydralazine hydrochloride"“isosorbide nitrate therapy." This statement should read that lower levels of available nitric oxide in black people are associated with adverse heart failure outcomes and may be enhanced by hydralazine hydrochloride"“isosorbide nitrate therapy.

Conflict of Interest:

None declared

Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)